Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

(2019) Robert Croop et al.   LANCET

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

(2019) Richard B. Lipton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lasmiditan is an effective acute treatment for migraine

(2018) Bernice Kuca et al.   NEUROLOGY

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

(2016) Tiffini Voss et al.   CEPHALALGIA

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis

(2016) Steven E. Nissen et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies

(2015) Michael J. Marmura et al.   HEADACHE

The International Classification of Headache Disorders, 3rd edition (beta version)

(2013)   CEPHALALGIA

BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial

(2013) Ronald Marcus et al.   CEPHALALGIA

Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators

(2012) et al.   CEPHALALGIA